Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy

Divyanshu Dubey, Niyatee Samudra, Puneet Gupta, Mark Agostini, Kan Ding, Paul C. Van Ness, Steven Vernino, Ryan Hays

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose Analyze clinical and electrographic characteristics of patients with autoimmune epilepsy, and evaluate the effect of early diagnosis and treatment on reduction of seizure frequency. Methods Observational retrospective case series, conducted using electronic medical data from two teaching hospitals. Clinical data was collected from 2008 to 2013. Cases of new onset seizures were selected based on the presence of laboratory evidence of autoimmunity. Results 34 hospitalized patients who presented predominantly due to seizures with concern for autoimmune etiology were identified. Mean age of patients was 44.94 years and 64.7% were males. Autoimmune antibodies were detected in 76.5% (26) of patients as follows: VGKc (8); NMDA-R (7); anti-thyroid (5); GAD (4); GABA<inf>B</inf> (2). 22 patients had unilateral temporal lobe onset and 4 had bilateral temporal lobe onset, while 8 had extra-temporal onset/multiple ictal foci. Median number of seizures during initial prolonged vEEG monitoring was 8 (range 0-48); median number of anti-seizure medications used was 2 (range 1-5). 9 patients had an underlying malignancy. 94.1% (32) patients received immunomodulation, as follows: high dose corticosteroids (96.8%), plasmapheresis (62.5%), IVIG (34.4%), rituximab (21.8%), mycophenolate (15.6%), cyclophosphamide (12.5%). 63.3% (19) participants achieved ≥50% seizure reduction (Responder Rate) at first clinic visit. Patients without malignancy had better seizure control (p < 0.05). Time from symptom onset to diagnosis (p < 0.005) and symptom onset to immunomodulation (p < 0.005) was significantly lower among patients who achieved responder rate (RR). Conclusion This study highlights certain important clinical and electrographic aspects of autoimmune epilepsy, and the significance of early diagnosis and initiation of immunomodulatory therapy.

Original languageEnglish (US)
Pages (from-to)143-147
Number of pages5
JournalSeizure
Volume29
DOIs
StatePublished - Jul 1 2015

Fingerprint

Epilepsy
Seizures
Immunomodulation
Temporal Lobe
Early Diagnosis
Medical Electronics
Plasmapheresis
Intravenous Immunoglobulins
N-Methylaspartate
Ambulatory Care
Autoimmunity
Teaching Hospitals
Cyclophosphamide
Neoplasms
Adrenal Cortex Hormones
Thyroid Gland
Stroke
Antibodies

Keywords

  • Epilepsy
  • Immunomodulation
  • Limbic encephalitis
  • Paraneoplastic syndrome

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy. / Dubey, Divyanshu; Samudra, Niyatee; Gupta, Puneet; Agostini, Mark; Ding, Kan; Van Ness, Paul C.; Vernino, Steven; Hays, Ryan.

In: Seizure, Vol. 29, 01.07.2015, p. 143-147.

Research output: Contribution to journalArticle

@article{042e8dbcac2a4067af1a9b444d6a2ad1,
title = "Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy",
abstract = "Purpose Analyze clinical and electrographic characteristics of patients with autoimmune epilepsy, and evaluate the effect of early diagnosis and treatment on reduction of seizure frequency. Methods Observational retrospective case series, conducted using electronic medical data from two teaching hospitals. Clinical data was collected from 2008 to 2013. Cases of new onset seizures were selected based on the presence of laboratory evidence of autoimmunity. Results 34 hospitalized patients who presented predominantly due to seizures with concern for autoimmune etiology were identified. Mean age of patients was 44.94 years and 64.7{\%} were males. Autoimmune antibodies were detected in 76.5{\%} (26) of patients as follows: VGKc (8); NMDA-R (7); anti-thyroid (5); GAD (4); GABAB (2). 22 patients had unilateral temporal lobe onset and 4 had bilateral temporal lobe onset, while 8 had extra-temporal onset/multiple ictal foci. Median number of seizures during initial prolonged vEEG monitoring was 8 (range 0-48); median number of anti-seizure medications used was 2 (range 1-5). 9 patients had an underlying malignancy. 94.1{\%} (32) patients received immunomodulation, as follows: high dose corticosteroids (96.8{\%}), plasmapheresis (62.5{\%}), IVIG (34.4{\%}), rituximab (21.8{\%}), mycophenolate (15.6{\%}), cyclophosphamide (12.5{\%}). 63.3{\%} (19) participants achieved ≥50{\%} seizure reduction (Responder Rate) at first clinic visit. Patients without malignancy had better seizure control (p < 0.05). Time from symptom onset to diagnosis (p < 0.005) and symptom onset to immunomodulation (p < 0.005) was significantly lower among patients who achieved responder rate (RR). Conclusion This study highlights certain important clinical and electrographic aspects of autoimmune epilepsy, and the significance of early diagnosis and initiation of immunomodulatory therapy.",
keywords = "Epilepsy, Immunomodulation, Limbic encephalitis, Paraneoplastic syndrome",
author = "Divyanshu Dubey and Niyatee Samudra and Puneet Gupta and Mark Agostini and Kan Ding and {Van Ness}, {Paul C.} and Steven Vernino and Ryan Hays",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.seizure.2015.04.007",
language = "English (US)",
volume = "29",
pages = "143--147",
journal = "Seizure : the journal of the British Epilepsy Association",
issn = "1059-1311",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy

AU - Dubey, Divyanshu

AU - Samudra, Niyatee

AU - Gupta, Puneet

AU - Agostini, Mark

AU - Ding, Kan

AU - Van Ness, Paul C.

AU - Vernino, Steven

AU - Hays, Ryan

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Purpose Analyze clinical and electrographic characteristics of patients with autoimmune epilepsy, and evaluate the effect of early diagnosis and treatment on reduction of seizure frequency. Methods Observational retrospective case series, conducted using electronic medical data from two teaching hospitals. Clinical data was collected from 2008 to 2013. Cases of new onset seizures were selected based on the presence of laboratory evidence of autoimmunity. Results 34 hospitalized patients who presented predominantly due to seizures with concern for autoimmune etiology were identified. Mean age of patients was 44.94 years and 64.7% were males. Autoimmune antibodies were detected in 76.5% (26) of patients as follows: VGKc (8); NMDA-R (7); anti-thyroid (5); GAD (4); GABAB (2). 22 patients had unilateral temporal lobe onset and 4 had bilateral temporal lobe onset, while 8 had extra-temporal onset/multiple ictal foci. Median number of seizures during initial prolonged vEEG monitoring was 8 (range 0-48); median number of anti-seizure medications used was 2 (range 1-5). 9 patients had an underlying malignancy. 94.1% (32) patients received immunomodulation, as follows: high dose corticosteroids (96.8%), plasmapheresis (62.5%), IVIG (34.4%), rituximab (21.8%), mycophenolate (15.6%), cyclophosphamide (12.5%). 63.3% (19) participants achieved ≥50% seizure reduction (Responder Rate) at first clinic visit. Patients without malignancy had better seizure control (p < 0.05). Time from symptom onset to diagnosis (p < 0.005) and symptom onset to immunomodulation (p < 0.005) was significantly lower among patients who achieved responder rate (RR). Conclusion This study highlights certain important clinical and electrographic aspects of autoimmune epilepsy, and the significance of early diagnosis and initiation of immunomodulatory therapy.

AB - Purpose Analyze clinical and electrographic characteristics of patients with autoimmune epilepsy, and evaluate the effect of early diagnosis and treatment on reduction of seizure frequency. Methods Observational retrospective case series, conducted using electronic medical data from two teaching hospitals. Clinical data was collected from 2008 to 2013. Cases of new onset seizures were selected based on the presence of laboratory evidence of autoimmunity. Results 34 hospitalized patients who presented predominantly due to seizures with concern for autoimmune etiology were identified. Mean age of patients was 44.94 years and 64.7% were males. Autoimmune antibodies were detected in 76.5% (26) of patients as follows: VGKc (8); NMDA-R (7); anti-thyroid (5); GAD (4); GABAB (2). 22 patients had unilateral temporal lobe onset and 4 had bilateral temporal lobe onset, while 8 had extra-temporal onset/multiple ictal foci. Median number of seizures during initial prolonged vEEG monitoring was 8 (range 0-48); median number of anti-seizure medications used was 2 (range 1-5). 9 patients had an underlying malignancy. 94.1% (32) patients received immunomodulation, as follows: high dose corticosteroids (96.8%), plasmapheresis (62.5%), IVIG (34.4%), rituximab (21.8%), mycophenolate (15.6%), cyclophosphamide (12.5%). 63.3% (19) participants achieved ≥50% seizure reduction (Responder Rate) at first clinic visit. Patients without malignancy had better seizure control (p < 0.05). Time from symptom onset to diagnosis (p < 0.005) and symptom onset to immunomodulation (p < 0.005) was significantly lower among patients who achieved responder rate (RR). Conclusion This study highlights certain important clinical and electrographic aspects of autoimmune epilepsy, and the significance of early diagnosis and initiation of immunomodulatory therapy.

KW - Epilepsy

KW - Immunomodulation

KW - Limbic encephalitis

KW - Paraneoplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84930975934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930975934&partnerID=8YFLogxK

U2 - 10.1016/j.seizure.2015.04.007

DO - 10.1016/j.seizure.2015.04.007

M3 - Article

VL - 29

SP - 143

EP - 147

JO - Seizure : the journal of the British Epilepsy Association

JF - Seizure : the journal of the British Epilepsy Association

SN - 1059-1311

ER -